Metastatic breast cancer progressing after anthracycline and

Anthracycline containing regimens or

Neutropenia: a condition in which a person has a low number of neutrophils, which are a specific type of white blood cell important for fighting infection. Overall survival OS : the percentage of people in a study who are still alive after a certain period of time.

Newsletter Stay up to date on cancer updates, research and education Subscribe Now! As a result of increasing anthracycline use earlier in the course of breast cancer, oncologists are frequently faced with the challenge of treating patients whose disease has progressed during or following anthracycline therapy or who are ineligible for further anthracycline therapy.

In terms of treatment-related side effects, the incidence of all-grade and at least grade 3 severe treatment-related side effects was comparable between investigational and control arms. Stomatitis: a general term for inflammation or soreness inside the mouth, which can include mouth sores.

Anthracycline containing and taxane

Disease control rate DCR : the percentage of patients in a study whose cancer either shrinks, disappears, or remains stable with treatment. Treatment discontinuation occurred in 87 and patients in the investigational and control arms, respectively.

Sac-TMT reduced the risk of disease progression or death by 65% and showed consistent benefits across subgroups. Our findings show that S-1 is non-inferior to the standard treatment group, anthracycline-containing regimens or taxane, with respect to overall survival and almost similar with regard to its effects on health-related quality of life as first-line chemotherapy for patients with HER2-negative metastatic breast cancer.

These new statistically significant and clinically meaningful efficacy data from OptiTROP-Breast02, along with an observed manageable safety profile, strengthen the case for sac-TMT as a potential new treatment option for this patient population who comprise a vast majority of global breast cancer cases.

Beta blockade enhances anthracycline

The safety profile of sac-TMT was manageable, with hematologic toxicities being the most common treatment-related side effects. By. Increasing use of standard chemotherapy, especially anthracycline- and taxane-based therapies, in early-stage breast cancer has led to a corresponding increase in heavily pretreated and/or treatment-resistant cases of metastatic breast cancer (MBC).

ECOG performance status: a scale that doctors use to describe a patient's general well-being and how capable they are of performing ordinary daily tasks. Glossary Progression-free survival PFS : the length of time a person lives with cancer without the cancer getting worse.

At a median follow-up of 7. This most recent report of safety data revealed a manageable safety profile, with no new safety signals. Anemia: a condition where your body does not have enough healthy red blood cells to carry adequate oxygen to your tissues, often leading to fatigue.

TUKYSA Combination Significantly Improves

Abstract LBA News Articles October 19, Fact checked by: Jason M Broderick. Additionally, an interim analysis of overall survival OS revealed a positive trend among those receiving sac-TMT compared to those receiving chemotherapy.

The most common treatment-related side effects for both sac-TMT and chemotherapy were hematologic toxicities, including decreased white blood cell count, anemia and neutropenia. Objective response rate ORR : the percentage of patients in a study whose cancer shrinks or disappears after treatment.

The study is assessing the primary end point of PFS, along with secondary end points of investigator-assessed OS, objective response rate, disease control rate and duration of response. Duration of response DOR : the length of time a patient continues to have a response to a treatment without the cancer progressing.

Atezolizumab plus anthracycline based

TUKYSA is approved in combination with trastuzumab and capecitabine to treat adults with HER2-positive advanced unresectable or metastatic breast cancer, including patients with brain metastases who have received one or more prior anti-HER2 breast cancer treatments in the metastatic setting.

Thus, second and later lines of MBC therapy frequently involve the clinically challenging picture of progressive disease and limited treatment. Overview Metastatic breast cancer (MBC) remains incurable despite the many advances in cancer treatment.

Patient characteristics were well balanced between the study arms. While anthracycline- and/or taxane-based regimens are the preferred first-line chemotherapies for MBC, many patients develop disease that is either resistant or becomes refractory to these agents.

Regimens with higher cumulative doses of anthracycline plus taxane provide the greatest benefits, challenging the current trend in clinical practice and guidelines towards non-anthracycline chemotherapy, particularly shorter regimens, such as four cycles of docetaxel–cyclophosphamide.

Currently, there is no single standard of care for women who experience disease progression. Anthracycline plus taxane regimens are most efficacious at reducing breast cancer recurrence and death. The most common reason for discontinuation was radiographic disease progression in both the investigational arm 80 patients and control arm patients.

Key Takeaways Sacituzumab tirumotecan (sac-TMT) significantly improved progression-free survival compared to chemotherapy in HR-positive, HER2-negative breast cancer patients. Progression-free survival PFS : the length of time a person lives with cancer without the cancer getting worse.